

# Elena Verzoni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2277829/publications.pdf>

Version: 2024-02-01

89  
papers

1,703  
citations

331670

21  
h-index

315739

38  
g-index

91  
all docs

91  
docs citations

91  
times ranked

2295  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). Expert Review of Anticancer Therapy, 2022, 22, 115-121.	2.4	5
2	Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 910.	7.1	20
3	Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. Tumori, 2021, 107, 542-549.	1.1	4
4	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. Expert Review of Clinical Pharmacology, 2021, 14, 261-268.	3.1	8
5	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). Frontiers in Oncology, 2021, 11, 682449.	2.8	16
6	Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 3807.	3.7	17
7	Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?. Current Oncology Reports, 2021, 23, 147.	4.0	15
8	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncology, The, 2020, 21, 95-104.	10.7	160
9	Current Understanding of Urachal Adenocarcinoma and Management Strategy. Current Oncology Reports, 2020, 22, 9.	4.0	23
10	Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?. Journal of Clinical Medicine, 2020, 9, 930.	2.4	25
11	Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. Future Oncology, 2019, 15, 2657-2666.	2.4	1
12	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. European Urology Oncology, 2019, 2, 699-707.	5.4	38
13	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. Clinical Genitourinary Cancer, 2019, 17, 291-298.	1.9	30
14	The role of metastasectomy in advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 603-611.	2.4	7
15	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 42-45.	1.3	20
16	Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. Clinical Genitourinary Cancer, 2018, 16, e735-e742.	1.9	14
17	A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial. Journal of Clinical Oncology, 2018, 36, 4502-4502.	1.6	7
18	What advances have been made in immune-therapy for renal cell carcinoma?. Future Oncology, 2017, 13, 665-668.	2.4	0

#	ARTICLE	IF	CITATIONS
19	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 183-188.	3.2	20
20	Multimodal treatment of advanced renal cancer in 2017. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1395-1402.	3.1	23
21	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. <i>Oncology</i> , 2017, 92, 269-275.	1.9	5
22	Treatment of Advanced Renal Cell Carcinoma: Recent Advances and Current Role of Immunotherapy, Surgery, and Cryotherapy. <i>Tumori</i> , 2017, 103, 15-21.	1.1	8
23	Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2167-2172.	4.3	15
24	Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice. <i>Translational Andrology and Urology</i> , 2016, 5, 974-976.	1.4	2
25	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0151662.	2.5	56
26	Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2016, 8, 319-326.	2.0	25
27	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 52-64.	4.4	19
28	Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 323-330.	3.2	13
29	Adjuvant treatment for renal cell carcinoma: in the long run will we get the same answers?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 803-804.	2.4	3
30	Treatment of elderly patients with metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 323-334.	2.4	9
31	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 33381-33390.	1.8	11
32	Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016, 7, 40085-40094.	1.8	17
33	Predicting Molecular Models: Where Are We Going?. <i>EBioMedicine</i> , 2015, 2, 1594-1595.	6.1	0
34	Tokio Rationale and Protocol: A Phase II Study to Evaluate the Activity and Safety of Third-line Tyrosine Kinase Inhibitor after 2 Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. <i>Tumori</i> , 2015, 101, 701-703.	1.1	1
35	Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 479-482.	1.3	26
36	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2015, 9, 263.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Hyponatremia in Cancer Patients. <i>Tumori</i> , 2015, 101, 246-248.	1.1	10
38	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. <i>Therapeutic Advances in Urology</i> , 2015, 7, 59-68.	2.0	2
39	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 1905-1910.	0.4	11
40	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015, 26, 2107-2113.	1.2	85
41	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 332.e19-332.e24.	1.6	12
42	Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. <i>Oncology</i> , 2015, 88, 133-138.	1.9	4
43	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 385-391.e1.	1.9	4
44	Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 152-161.	2.0	27
45	Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 137-141.	1.9	28
46	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.4	58
47	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. <i>PLoS ONE</i> , 2015, 10, e0120427.	2.5	9
48	Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis. <i>Current Drug Targets</i> , 2015, 16, 164-170.	2.1	47
49	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. <i>Canadian Urological Association Journal</i> , 2014, 8, 121.	0.6	8
50	Targeted treatments in advanced renal cell carcinoma: focus on axitinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 107.	0.7	5
51	Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 497-510.	2.4	9
52	First line treatment of metastatic renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2014, 15, 19-21.	3.4	7
53	Response to Targeted Therapy in Urachal Adenocarcinoma. <i>Rare Tumors</i> , 2014, 6, 124-127.	0.6	20
54	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014, 10, 1361-1372.	2.4	9

#	ARTICLE	IF	CITATIONS
55	Butterfly and Renal Cell Cancer: Out of Chaos Comes Order. <i>Journal of Clinical Oncology</i> , 2014, 32, 3083-3083.	1.6	2
56	Study design and clinical evidence in mRCC. <i>Cancer Biology and Therapy</i> , 2014, 15, 486-488.	3.4	2
57	Safety profile and treatment response of everolimus in different solid tumors: an observational study. <i>Future Oncology</i> , 2014, 10, 1611-1617.	2.4	8
58	Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. <i>Tumori</i> , 2014, 100, e282-e285.	1.1	0
59	Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma. <i>Tumori</i> , 2014, 100, e282-5.	1.1	0
60	Prognostic Role of Pancreatic Metastases From Renal Cell Carcinoma: Results From an Italian Center. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 484-488.	1.9	41
61	Complete responses in advanced renal cell carcinoma: Utopia or real chance?. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 151-152.	1.6	1
62	Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. <i>Future Oncology</i> , 2013, 9, 1599-1607.	2.4	7
63	Targeted Therapies and Survival: What We Can Learn from Studies in Advanced Renal Cell Carcinoma. <i>Oncology</i> , 2013, 84, 39-42.	1.9	4
64	Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. <i>Annals of Oncology</i> , 2013, 24, 2967-2971.	1.2	22
65	Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1089-1096.	2.4	5
66	Experience with sorafenib in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2012, 4, 303-313.	2.0	17
67	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>British Journal of Cancer</i> , 2012, 107, 1227-1232.	6.4	18
68	New Perspectives in Advanced Genitourinary Malignancies. <i>Tumori</i> , 2012, 98, 267-269.	1.1	3
69	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 464-467.	1.6	33
70	Complete Response After Sequential Sunitinib-Sorafenib Treatment in a Patient With Renal Cell Carcinoma: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 130-133.	1.9	3
71	Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-833. <i>European Urology</i> , 2012, 62, e5-e6.	1.9	3
72	New perspectives in advanced genitourinary malignancies. <i>Tumori</i> , 2012, 98, 267-9.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Management of advanced genitourinary tumors. Tumori, 2012, 98, 264-6.	1.1	0
74	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU International, 2011, 108, E250-E257.	2.5	79
75	Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. British Journal of Cancer, 2011, 104, 1256-1261.	6.4	66
76	Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Review of Anticancer Therapy, 2011, 11, 1631-1640.	2.4	17
77	Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma. Medical Oncology, 2010, 27, 1267-1268.	2.5	2
78	Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma?. Tumori, 2010, 96, 794-795.	1.1	2
79	Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?. Tumori, 2010, 96, 794-5.	1.1	1
80	Feasibility Study of Biweekly Capecitabine, Oxaliplatin, and Irinotecan in Patients with Untreated Advanced Gastric Cancer. Tumori, 2009, 95, 43-47.	1.1	9
81	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncology Reviews, 2009, 3, 79-87.	1.8	3
82	252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC). European Urology Supplements, 2009, 8, 183.	0.1	19
83	A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. Journal of Clinical Oncology, 2009, 27, 5099-5099.	1.6	3
84	Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer. Tumori, 2009, 95, 43-7.	1.1	6
85	Pulmonary Carcinoid Tumours: Indolent but Not Benign. Oncology, 2007, 73, 162-168.	1.9	29
86	Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma. Oncology, 2007, 73, 204-209.	1.9	30
87	Renal Cell Cancer and Sorafenib: Skin Toxicity and Treatment Outcome. Tumori, 2007, 93, 201-203.	1.1	7
88	Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemotherapy and Pharmacology, 2007, 59, 637-642.	2.3	218
89	Neuroendocrine Tumors of the Larynx: A Clinical Report and Literature Review. Tumori, 2006, 92, 72-75.	1.1	17